drugset / Trial / NCT06009965
Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this study, investigators intend to prospectively study treatment-naive AA patients (including SAA and NSAA) who are non-transplant candidates in northern China. Patients with SAA receive ATG+CsA+Herombopag, and patients with NSAA receive CsA+ Herombopag. Investigators explored possible indicators of participants' predictive efficacy and built predictive models. After the participants achieved response, they used a tapering regimen, observed relapse and clonal evolution, and developed a predictive model of relapse.
Timeline
- Start
- 2023-01-20
- Primary completion
- 2025-01-30
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CsA | Unknown | 3 mg/kg | — |
| Subject | CsA | Unknown | 5 mg/kg | — |
| Subject | RAFUTROMBOPAG | Other / unclassified | 15 mg | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 3 mg/kg | — |
| Subject | porcine anti-lymphocyte immunoglobulin | Protein / enzyme biologic | 25 mg/kg | — |